இக்மிர் தேசிய நிறுவனம் ஆஃப் வைராலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இக்மிர் தேசிய நிறுவனம் ஆஃப் வைராலஜி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இக்மிர் தேசிய நிறுவனம் ஆஃப் வைராலஜி Today - Breaking & Trending Today

COVAXIN effective against UK, Brazil variants of SARS-CoV-2: ICMR


COVAXIN effective against UK, Brazil variants of SARS-CoV-2: ICMR
BusinessToday.In
© India Today Group
COVAXIN effective against UK, Brazil variants of SARS-CoV-2: ICMR
The Indian Council of Medical Research (ICMR) has said that Bharat Biotech s coronavirus vaccine COVAXIN is effective against various variants of the novel SARS-CoV-2. The ICMR added that the indigenously developed vaccine is also effective against the double mutant strain.
COVAXIN was developed in collaboration with Bharat Biotech, the ICMR and the National Institute of Virology. This vaccine was developed using a coronavirus sample isolated by the NIV.
COVAXIN has received emergency use authorisations in India and other countries globally. The ICMR tweeted, ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. ....

New Zealand , Hong Kong , United Kingdom , South Africa , Mehak Agarwal , National Institute Of Virology , Icmr National Institute Of Virology , Indian Council Of Medical Research , India Today Group , Indian Council , Medical Research , Bharat Biotech , National Institute , புதியது ஜீலாந்து , ஹாங் காங் , ஒன்றுபட்டது கிஂக்டம் , மெஹாக் அகர்வால் , தேசிய நிறுவனம் ஆஃப் வைராலஜி , இக்மிர் தேசிய நிறுவனம் ஆஃப் வைராலஜி , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , இந்தியா இன்று குழு , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி , பாரத் பயோடெக் , தேசிய நிறுவனம் ,

Coronavirus | Covaxin gets central drugs authority panel approval for restricted use


Coronavirus | Covaxin gets central drugs authority panel approval for restricted use
Updated:
Updated:
Bharat Biotech’s vaccine candidate approved for use in clinical trial mode.
Share Article
AAA
A health worker administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, during phase- 3 trials for the vaccine candidate at the People’s Medical College in Bhopal on December 7, 2020.   | Photo Credit:
PTI
Bharat Biotech’s vaccine candidate approved for use in clinical trial mode.
India’s first indigenously developed COVID-19 vaccine, Covaxin, has been recommended for “restricted use in emergency situation, subject to multiple regulatory conditionalties” by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), here on Saturday. The Drugs Controller General (DCGI) will take a final call on approving rollout of the vaccine in the country. ....

United Kingdom , Rahul Pandit , Arvind Soin , Indian Council Of Medical Research , Health Ministry , Central Drugs Standard Control Organisation , Icmr National Institute Of Virology , Pune Serum Institute Of India , Expert Committee , Serum Institute Of India , Oxford University , Subject Expert Committee , Drugs Controller General , Serum Institute , Bharat Biotech , Liver Transplant Unit , Medanta Hospital Arvind Soin , Indian Council , Medical Research , United Kingdom Variant , United Kingdom Returnees , ஒன்றுபட்டது கிஂக்டம் , ராகுல் பண்டிட் , அரவிந்த் மண் , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , ஆரோக்கியம் அமைச்சகம் ,

New UK strain threat: India to begin genome sequencing of genes of 5% Covid +ve samples


URL copied
Image Source : PTI
New UK strain threat: India to begin genome sequencing of genes of 5% Covid +ve samples
The National Task Force on Covid-19 has recommended that as part of “prospective surveillance”, 5% of positive cases from all states and UTs be tested for whole-genome sequencing to check for the presence of the “UK strain” that is seen to have a higher degree of infectiousness.
The moves come weeks after the UK found a variant with an unusually high number of changes, including some that are believed to make the virus 56%-70% more transmissible. The new strain is yet not known to cause more severe disease or make the current class of vaccines ineffective. ....

Andhra Pradesh , United Kingdom , New Delhi , Institute Of Biomedical Genomics , Union Health Ministry , National Centre For Biological Sciences , Institute Of Life Sciences , Csir Centre For Cellular , Bureau Of Immigration , National Centre For Disease , Health Ministry , National Task Force On Covid , Icmr National Institute Of Virology , National Institute Of Mental Health Neurosciences , New United Kingdom , Image Source , National Task Force , Receptor Binding Domain , Whole Genome Sequencing , Surveillance Units , District Surveillance Units , Disease Control , Integrative Biology , Molecular Biology , Life Sciences , National Institute ,